Leadership Expansion at Aquestive Therapeutics
Aquestive Therapeutics, Inc. (NASDAQ: AQST) has announced an important shift in its leadership team to strategically support the expected launch of Anaphylm™ (dibutepinephrine) Sublingual Film, pending FDA approval, while accelerating the company's ongoing initiatives. The changes are part of a broader effort to ensure the effective development of products that significantly enhance patients' lives.
New Roles and Responsibilities
Matthew Davis, M.D., RPh, joins the team immediately as the Chief Development Officer, bringing extensive experience in the pharmaceutical sector. Gary Slatko, M.D., M.B.A., steps in as the interim Chief Medical Officer, with a wealth of experience from regulatory science and drug safety. Peter Boyd, M.B.A., has been promoted to Chief People Officer, reflecting his notable contributions to the organization since joining in 2013.
Matthew Davis, Chief Development Officer
Dr. Matthew Davis will lead the research & development and clinical pipeline efforts within the company. With over two decades in drug development, he has held significant roles in various companies and is recognized for his contributions, including multiple FDA approvals and patents.
Gary Slatko's Return
Dr. Gary Slatko returns to Aquestive after previously serving as Chief Medical Officer, now to focus on medical affairs and pharmacovigilance. His seasoned background encompasses leadership roles across significant pharmaceutical companies and regulatory agencies, which will be vital for the advancement of Anaphylm™.
Recognizing Past Contributions
As changes unfold, the company expresses gratitude to Dr. Carl Kraus for his service as the Chief Medical Officer and honors Dr. Steve Wargacki, former Chief Science Officer, for his pivotal role in developing Anaphylm™ throughout nearly a decade of research. Their contributions have solidified the foundation of the company as it prepares for future challenges.
About Anaphylm™
Anaphylm™ is a novel sublingual film designed to provide rapid relief from severe allergic reactions. Its favorable design enables ease of use without the need for water or swallowing, distinguishing it as a potentially revolutionary approach in emergency allergy treatment, pending regulatory approval. The product is characterized by its portability and durability, appealing traits for individuals managing severe allergies.
Strategic Plans Ahead
These leadership changes come as the company gears up for a significant phase of growth. The commitment to enhancing its pipeline reflects a broader strategy to advance innovative therapeutic options, particularly through the AdrenaVerse™ prodrug epinephrine platform. By integrating seasoned leaders into crucial roles, Aquestive hopes to bolster its mission to transform patient care.
About Aquestive Therapeutics
Aquestive is dedicated to advancing medications that significantly improve patients' lives through innovative science and delivery technologies. The company is working diligently to develop products that present non-invasive alternatives for administering complicated molecules, striving to meet the healthcare needs of various patient populations.
Frequently Asked Questions
What recent changes occurred in the leadership of Aquestive Therapeutics?
Aquestive has appointed Dr. Matthew Davis as Chief Development Officer, Dr. Gary Slatko as interim Chief Medical Officer, and promoted Peter Boyd to Chief People Officer.
What is Anaphylm™ and why is it significant?
Anaphylm™ is a sublingual film designed to treat severe allergic reactions. Its unique delivery method and portability may revolutionize emergency allergy management.
How does Dr. Matthew Davis's experience contribute to the team?
Dr. Davis brings over 20 years of experience in drug development and has been instrumental in numerous FDA approvals, which will enhance the company’s research and development efforts.
What roles will Dr. Gary Slatko fulfill in his return?
In his role as interim Chief Medical Officer, Dr. Slatko will oversee medical affairs and pharmacovigilance, leveraging his extensive experience from previous leadership positions.
What is the future outlook for Questo Therapeutics?
The strategic leadership changes position Aquestive to successfully advance its product pipeline while focusing on significant growth initiatives in the coming years.
